Voyager nets $50.8mm through FOPO

14:40 EST 9 Nov 2017 | Elsevier Business Intelligence

Voyager Therapeutics Inc. (neurological disorder AAV gene therapies using gene replacement or gene knockdown) netted $50.8mm ...

Original Article: Voyager nets $50.8mm through FOPO


More From BioPortfolio on "Voyager nets $50.8mm through FOPO"

Quick Search


Relevant Topics

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...